180 related articles for article (PubMed ID: 33284639)
41. Validation of Two Calprotectin Rapid Tests in Daily Routine.
Schulz C; Wex T; Arnim UV; Malfertheiner P
Clin Lab; 2016 Jul; 62(7):1249-1254. PubMed ID: 28164652
[TBL] [Abstract][Full Text] [Related]
42. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
43. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation.
Chung-Faye G; Hayee B; Maestranzi S; Donaldson N; Forgacs I; Sherwood R
Inflamm Bowel Dis; 2007 Nov; 13(11):1374-8. PubMed ID: 17577247
[TBL] [Abstract][Full Text] [Related]
44. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
45. Fecal Calprotectin.
Ayling RM; Kok K
Adv Clin Chem; 2018; 87():161-190. PubMed ID: 30342711
[TBL] [Abstract][Full Text] [Related]
46. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.
Fukunaga S; Kuwaki K; Mitsuyama K; Takedatsu H; Yoshioka S; Yamasaki H; Yamauchi R; Mori A; Kakuma T; Tsuruta O; Torimura T
Int J Mol Med; 2018 Jan; 41(1):107-118. PubMed ID: 29115397
[TBL] [Abstract][Full Text] [Related]
47. Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease.
Jusué V; Chaparro M; Gisbert JP
Dig Liver Dis; 2018 Apr; 50(4):353-359. PubMed ID: 29396129
[TBL] [Abstract][Full Text] [Related]
48. The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease.
Zhulina Y; Cao Y; Amcoff K; Carlson M; Tysk C; Halfvarson J
Aliment Pharmacol Ther; 2016 Sep; 44(5):495-504. PubMed ID: 27402063
[TBL] [Abstract][Full Text] [Related]
49. Role of fecal calprotectin in the assessment of intestinal inflammation in children with familial Mediterranean fever.
Gucenmez OA; Kume T; Makay B; Babayigit O; Arslan N; Unsal E
Int J Rheum Dis; 2018 Oct; 21(10):1844-1848. PubMed ID: 30345692
[TBL] [Abstract][Full Text] [Related]
50. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome.
Sydora MJ; Sydora BC; Fedorak RN
J Crohns Colitis; 2012 Mar; 6(2):207-14. PubMed ID: 22325175
[TBL] [Abstract][Full Text] [Related]
51. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
[TBL] [Abstract][Full Text] [Related]
52. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
Sipponen T; Kolho KL
Scand J Gastroenterol; 2015 Jan; 50(1):74-80. PubMed ID: 25523558
[TBL] [Abstract][Full Text] [Related]
53. Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease.
Reinders CA; Jonkers D; Janson EA; Stockbrügger RW; Stobberingh EE; Hellström PM; Lundberg JO
Scand J Gastroenterol; 2007 Oct; 42(10):1151-7. PubMed ID: 17852876
[TBL] [Abstract][Full Text] [Related]
54. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
[TBL] [Abstract][Full Text] [Related]
55. Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease.
Lamers CR; de Roos NM; Bongers CCWG; Ten Haaf DSM; Hartman YAW; Witteman BJM; Hopman MTE
Scand J Gastroenterol; 2021 Jan; 56(1):30-37. PubMed ID: 33211989
[TBL] [Abstract][Full Text] [Related]
56. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
Sidler MA; Leach ST; Day AS
Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
58. E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
Elkjaer M
Dan Med J; 2012 Jul; 59(7):B4478. PubMed ID: 22759851
[TBL] [Abstract][Full Text] [Related]
59. Automated Fecal Biomarker Profiling - a Convenient Procedure to Support Diagnosis for Patients with Inflammatory Bowel Diseases.
Kraemer A; Bulgakova T; Schukina O; Kharitidis A; Kharitonov A; Korostovtseva E; Hammar F; Bang H; Lapin S
Clin Lab; 2020 Jul; 66(7):. PubMed ID: 32658433
[TBL] [Abstract][Full Text] [Related]
60. Fecal Calprotectin Is Not Affected by Pregnancy: Clinical Implications for the Management of Pregnant Patients with Inflammatory Bowel Disease.
Julsgaard M; Hvas CL; Gearry RB; Vestergaard T; Fallingborg J; Svenningsen L; Kjeldsen J; Sparrow MP; Wildt S; Kelsen J; Bell SJ
Inflamm Bowel Dis; 2017 Jul; 23(7):1240-1246. PubMed ID: 28498159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]